The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer

  • Technology appraisal guidance
  • TA33
  • Published: 

This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].